TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06230705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self management
Description: Self management
Study: NCT04527406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior hemivertebra resection
Description: The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment+ delayed posterior hemivertebra resection
Description: In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
Study: NCT04888377

Intervention type: DRUG
Intervention: Aspirin
Description: Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.

Intervention type: DRUG
Intervention: Placebo
Description: Participant's mothers were administered placebo throughout their pregnancy with the participant.
Study: NCT04288960

Intervention type: DEVICE
Intervention: Gwalk accelerometer walking trials
Description: No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
Study: NCT06111976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.
Study: NCT05131152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
Description: oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
Description: oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
Study: NCT05568875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-self-management intervention (Happy Hands app)
Description: The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
Study: NCT05184491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naïve patients - ACO therapy
Description: Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naïve patients - LNDL therapy
Description: Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naïve patients - MNDL therapy
Description: Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment-experienced patients- LNDL therapy
Description: Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment-experienced patients- MNDL therapy
Description: Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Study: NCT05416268

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroretinography
Description: Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroretinography
Description: Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroretinography
Description: Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
Study: NCT05649865

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples for analysis of circulating tumour HPVDNA
Study: NCT06126185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12-week course of synbiotic
Description: A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
Study: NCT06329375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition program
Description: Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
Study: NCT06230276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast
Description: Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
Study: NCT05295459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: LYR-210 drug matrix (mometasone furoate)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham procedure control
Description: Sham procedure control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Daily Saline Irrigation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Background therapy
Description: Daily Saline Irrigation
Study: NCT05934682

Intervention type: PROCEDURE
Intervention: Surgery
Description: All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
Study: NCT05818046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transcutaneous oxygen pressure
Description: External proxe fixed to the skin and ultrasound examination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Exercise therapy
Description: Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
Study: NCT04988035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Danicopan matching placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Danicopan matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study: NCT06313710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head down position
Description: -10° Trendelenburg
Study: NCT04988035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study: NCT05628818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct current Stimulation
Description: Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
Study: NCT05318703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tai ji quan
Description: cognitively enhanced tai ji quan exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching exercise
Study: NCT05435664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: It consists of sessions involving deep breathing and stretching and relaxing the body.
Study: NCT05599737

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integrated boost
Description: Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
Study: NCT04833816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of drug
Description: Administration of ketamin during the 48h after trauma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of drug
Description: Administration of ketamin during the 48h after trauma
Study: NCT06368791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Box Breathing
Description: Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and Mindfulness Exercise
Description: The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday life control
Description: Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday life control
Description: Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
Study: NCT04854551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be used to control for expectancy effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be used to control for expectancy effects
Study: NCT05855772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves
Description: Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posture Correction Exercise Program
Description: The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Posture Correction Exercise Program
Description: The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
Study: NCT05821244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Timing Groups
Description: Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Timing Groups
Description: Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
Study: NCT04353739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management for HIV-positive Asian Pacific Americans
Description: Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management for HIV-positive Asian Pacific Americans
Description: Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
Study: NCT05617781

Intervention type: BEHAVIORAL
Intervention: Questionnary
Description: The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)

Intervention type: BEHAVIORAL
Intervention: Questionnary
Description: The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
Study: NCT04218409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oral oxycodone 5 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oral oxycodone 5 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal oxytocin administration (48 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal oxytocin administration (48 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal oxytocin administration (48 IU)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxycodone
Description: Oxycodone 0 mg orally

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Oxycodone
Description: Oxycodone 0 mg orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oxytocin
Description: Intranasal placebo administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oxytocin
Description: Intranasal placebo administration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo oxytocin
Description: Intranasal placebo administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oral oxycodone 2.5 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oral oxycodone 2.5 mg orally
Study: NCT04234867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: once daily for 5 days
Study: NCT06334627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Primary Intervention
Description: School readiness intervention
Study: NCT04234867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: once daily for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress
Description: single dose after last administration of experimental drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stress
Description: single dose after last administration of experimental drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Stress
Description: single dose after last administration of experimental drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Stress
Description: single dose after last administration of experimental drug
Study: NCT05924594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.